Last reviewed · How we verify
Simmitinib tablets
At a glance
| Generic name | Simmitinib tablets |
|---|---|
| Sponsor | Shanghai Runshi Pharmaceutical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (PHASE1, PHASE2)
- A Phase I Trial of Simmitinib in Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Simmitinib tablets CI brief — competitive landscape report
- Simmitinib tablets updates RSS · CI watch RSS
- Shanghai Runshi Pharmaceutical Technology Co., Ltd portfolio CI